Stock Ratings / Health Care / COCP / financials

KYNB (44) PBM (61) AKTX (36) MCRB (54) ⌘ Pro Terminal →

Cocrystal Pharma Inc. (COCP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.98 -1.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.98

Cocrystal Pharma Inc. (COCP) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $18.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.98 (-0.37%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COCP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY COCP SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)

FRED Regime × Technicals: 17% of 52W Range • RSI-14 at 44.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.07-4.7% Next Q

Q2 (-2Q)

Grade D$1.02-6.9% Next Q

Q3 (-1Q)

Grade D$0.95+3.2% Next Q

Current

Grade D-$0.98-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a COCP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While COCP currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.10) and Max Pain ($1.03) forces dealer call-delta covering toward $2.13.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $COCP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “COCP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How COCP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.2%	-$8.8M	-$8.2M	-45%
FY 2024	$4.00B	52%	-0.4%	-$17.5M	-$16.5M	-45%
FY 2023	$4.00B	52%	-0.5%	-$18.0M	-$14.7M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COCP)

✓Walkthrough of COCP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

COCP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.47%📐 HORIZONTAL RANGE

2026-10-30O $0.95H $1.01L $0.95C $0.98VOL 62.8K

RES: $1.42SUP: $0.87SMA50: $1.10SMA200: $1.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

COCP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 COCP Butterfly Map → + Track COCP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on COCP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for COCP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for COCP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COCP)

Health Care Rank #592 of 1016 ⚔️ KYNB vs COCP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (COCP vs. KYNB, PBM, AKTX, MCRB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cocrystal Pharma Inc. (COCP) ranks #592 by composite RQD confidence (42/100, grade D-) and #838 by equity capitalization ($18.9M). Within this direct 5-issuer industry benchmark cohort, COCP leads on earnings valuation at N/A trailing P/E, while COCP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PBM currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with COCP at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
COCP ACTIVE Cocrystal Pharma Inc.	D-	42/100	—	—	-35.0%	-1.01%	$18.9M	Benchmark Subject
KYNB Kyntra Bio Inc.	D	44/100	—	91.4%	-35.0%	-1.48%	$18.8M	/kynb-vs-cocp →
PBM Psyence Biomedical Ltd.	C-	61/100	—	—	—	+6.18%	$19.2M	/pbm-vs-cocp →
AKTX Akari Therapeutics plc ADS	D-	36/100	—	—	-35.0%	-13.04%	$18.3M	/aktx-vs-cocp →
MCRB Seres Therapeutics Inc.	D+	54/100	—	—	-35.0%	+8.94%	$19.6M	/mcrb-vs-cocp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001412486

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cocrystal Pharma Inc. (COCP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.8M, operating cash flow of -$8.2M, and free cash flow of -$8.2M (+50.3% YoY). On the balance sheet, COCP closed FY2025 with $9.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$8.8M	-$8.2M	-$8.2M	$9.7M	—
FY2024 (FY)	2024-12-31	$0	-$17.5M	-$16.5M	-$16.5M	$13.5M	—
FY2023 (FY)	2023-12-31	$0	-$18.0M	-$14.7M	-$14.7M	—	—

3. COCP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is COCP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cocrystal Pharma Inc. (NASDAQ: COCP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.98 (-1.01% 1D, market cap $18.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, COCP ranks #592 in composite RQD confidence.

How does COCP compare to KYNB and PBM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COCP carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M) and PBM (Psyence Biomedical Ltd.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $19.2M). Among the 5-stock peer group, COCP leads on earnings multiple (N/A) while COCP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for COCP?

Per COCP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001412486), Cocrystal Pharma Inc. generated $0 in revenue, -$8.8M in net income, and -$8.2M in free cash flow against $9.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is COCP trading relative to its 50-day, 200-day, and 52-week technical levels?

COCP last traded at $0.98 (-1.01% on volume of 14,735 shares), positioning the stock -10.91% below its 50-day simple moving average ($1.10) and -10.91% below its 200-day simple moving average ($1.10). Across its 52-week range of $0.76 to $2.03, COCP sits at the 17.3% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).

COCP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Cocrystal Pharma Inc. (COCP)?

In FY 2025 (10-K), COCP converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: COCP RQD Cockpit COCP 12M Forecast COCP Earnings & Move COCP Dividends & DRIP COCP Insiders & 13F COCP Whale Options COCP Profit Sankey COCP News & Why